10-year analysis of the ATAC trial: Wrong conclusion? - Authors' reply

Jack Cuzick; Ivana Sestak; Michael Baum; Aman Buzdar; Anthony Howell; Mitch Dowsett; John F. Forbes

doi:10.1016/S1470-2045(11)70050-X

10-year analysis of the ATAC trial: Wrong conclusion? - Authors' reply

Jack Cuzick, Ivana Sestak, Michael Baum, Aman Buzdar, Anthony Howell, Mitch Dowsett, John F. Forbes

Breast Medical Oncology

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	217
Number of pages	1
Journal	The lancet oncology
Volume	12
Issue number	3
DOIs	https://doi.org/10.1016/S1470-2045(11)70050-X
State	Published - Mar 2011

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(11)70050-X

Cite this

@article{9f9ed7bad4164539a864247bde7aece0,

title = "10-year analysis of the ATAC trial: Wrong conclusion? - Authors' reply",

author = "Jack Cuzick and Ivana Sestak and Michael Baum and Aman Buzdar and Anthony Howell and Mitch Dowsett and Forbes, {John F.}",

note = "Funding Information: JC has received grants, honoraria, travel grants, and payment for lectures from AstraZeneca. IS has received travel support from AstraZeneca. AB has received a grant and travel support from AstraZeneca. AH has received travel support from AstraZeneca, consultancy fees from Genentech and Pfizer, payment for lectures from AstraZeneca, and money from Pfizer and Roche for Data Monitoring Committee meetings. MD has received travel support from AstraZeneca, board membership fees, grants, and payments for lectures from AstraZeneca and Novartis, and has a patent registered with Novartis. JFF has received honoraria and travel support from AstraZeneca. MB has no conflicts of interest.",

year = "2011",

month = mar,

doi = "10.1016/S1470-2045(11)70050-X",

language = "English (US)",

volume = "12",

pages = "217",

journal = "The lancet oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "3",

}

TY - JOUR

T1 - 10-year analysis of the ATAC trial

T2 - Wrong conclusion? - Authors' reply

AU - Cuzick, Jack

AU - Sestak, Ivana

AU - Baum, Michael

AU - Buzdar, Aman

AU - Howell, Anthony

AU - Dowsett, Mitch

AU - Forbes, John F.

N1 - Funding Information: JC has received grants, honoraria, travel grants, and payment for lectures from AstraZeneca. IS has received travel support from AstraZeneca. AB has received a grant and travel support from AstraZeneca. AH has received travel support from AstraZeneca, consultancy fees from Genentech and Pfizer, payment for lectures from AstraZeneca, and money from Pfizer and Roche for Data Monitoring Committee meetings. MD has received travel support from AstraZeneca, board membership fees, grants, and payments for lectures from AstraZeneca and Novartis, and has a patent registered with Novartis. JFF has received honoraria and travel support from AstraZeneca. MB has no conflicts of interest.

PY - 2011/3

Y1 - 2011/3

UR - http://www.scopus.com/inward/record.url?scp=79952013513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952013513&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(11)70050-X

DO - 10.1016/S1470-2045(11)70050-X

M3 - Letter

AN - SCOPUS:79952013513

SN - 1470-2045

VL - 12

SP - 217

JO - The lancet oncology

JF - The lancet oncology

IS - 3

ER -

10-year analysis of the ATAC trial: Wrong conclusion? - Authors' reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this